Literature DB >> 6324833

Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.

G P Hodsman, J R Zabludowski, C Zoccali, R Fraser, J J Morton, G D Murray, J I Robertson.   

Abstract

The immediate and long-term effects of enalapril (MK421) and its lysine analogue (MK521) in once-daily dosage, were compared in a study of 12 normal subjects. Both compounds lowered blood pressure equally throughout 24 h without causing tachycardia. The biochemical changes with MK521 were more sustained than with MK421, but this did not affect the magnitude of blood pressure reduction. Twenty-four hours after the previous dose, with both active drugs, plasma renin concentration was significantly higher on day 8 than on day 1, though angiotensin I did not increase in proportion; this probably reflects a fall in renin-substrate with prolonged converting enzyme inhibition. There was an early natriuresis with each compound but this effect was no longer apparent after 8 days of continuous therapy. Both MK421 and MK521 were well tolerated with no serious side effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6324833      PMCID: PMC1463367          DOI: 10.1111/j.1365-2125.1984.tb02337.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

Review 1.  Captopril in the treatment of clinical hypertension and cardiac failure.

Authors:  A B Atkinson; J I Robertson
Journal:  Lancet       Date:  1979-10-20       Impact factor: 79.321

2.  Measurement of concentrations of angiotensin I in human blood by radioimmunoassay.

Authors:  M A Waite
Journal:  Clin Sci       Date:  1973-07       Impact factor: 6.124

3.  A comparison of double-isotope derivative and radioimmunological estimation of plasma aldosterone concentration in man.

Authors:  R Fraser; S Guest; J Young
Journal:  Clin Sci Mol Med       Date:  1973-09

4.  Three new long-acting converting-enzyme inhibitors: relationship between plasma converting-enzyme activity and response to angiotensin I.

Authors:  J Biollaz; M Burnier; G A Turini; D B Brunner; M Porchet; H J Gomez; K H Jones; F Ferber; W B Abrams; H Gavras; H R Brunner
Journal:  Clin Pharmacol Ther       Date:  1981-05       Impact factor: 6.875

5.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

6.  The renin--angiotensin--aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects.

Authors:  G A MacGregor; N D Markandu; J E Roulston; J C Jones; J J Morton
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

7.  Angiotensin II and its heptapeptide (2-8), hexapeptide (3-8), and pentapeptide (4-8) metabolites in arterial and venous blood of man.

Authors:  P F Semple; A S Boyd; P M Dawes; J J Morton
Journal:  Circ Res       Date:  1976-11       Impact factor: 17.367

8.  des-Asp-angiotensin I: its identification in rat blood and confirmation as a substrate for converting enzyme.

Authors:  C Garcia Del Rio; W S Smellie; J J Morton
Journal:  Endocrinology       Date:  1981-02       Impact factor: 4.736

9.  Effect of N-[(S)-1-carboxy-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK-421) on angiotensin converting enzyme in vitro and angiotensin I pressor responses in vivo.

Authors:  D M Gross; C S Sweet; E H Ulm; E P Backlund; A A Morris; D Weitz; D L Bohn; H C Wenger; T C Vassil; C A Stone
Journal:  J Pharmacol Exp Ther       Date:  1981-03       Impact factor: 4.030

10.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Authors:  A B Atkinson; J J Morton; J J Brown; D L Davies; R Fraser; P Kelly; B Leckie; A F Lever; J I Robertson
Journal:  Br Heart J       Date:  1980-09
View more
  16 in total

1.  Effects of prolonged administration of the angiotensin converting enzyme inhibitor CGS 16617 in normotensive volunteers.

Authors:  G Waeber; M Burnier; M Porchet; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  A need for new converting enzyme inhibitors?

Authors:  S G Ball; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

3.  Age and the pharmacodynamics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.

Authors:  A A Ajayi; N Hockings; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1986-04       Impact factor: 4.335

4.  Effect on blood pressure and the renin-angiotensin system of repeated doses of the converting enzyme inhibitor CGS 14824A.

Authors:  G Waeber; T Fasanella d'Amore; J Nussberger; B Waeber; H R Brunner
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

5.  Lisinopril in hypertensive patients with and without renal failure.

Authors:  B A van Schaik; G G Geyskes; P Boer
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  The effect of enalapril (MK421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her foetus.

Authors:  F Broughton Pipkin; C P Wallace
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

7.  Changes in haemodynamics and body fluid volume due to enalapril in patients with essential hypertension on chronic diuretic therapy.

Authors:  B A van Schaik; G G Geyskes; P Boer; E J Dorhout Mees
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 8.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

9.  Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Authors:  Wei-Chi Liao; Ole Vesterqvist; Carol Delaney; Mohammed Jemal; Irene Ferreira; Neville Ford; Brian Swanson; Howard Uderman
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 10.  An overview of the clinical pharmacology of enalapril.

Authors:  R O Davies; H J Gomez; J D Irvin; J F Walker
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.